Gain Therapeutics(GANX)
$0.94-0.10 (-9.62%)
GANX
Gain Therapeutics hedge funds
$0.94
At close:-0.10 (-9.62%)
Want to see GANX full AI Analyst Report?
Gain Therapeutics (GANX) Hedge Fund Trading Activity
468 Followers
No recent Hedge Funds data found for GANX
Hedge Fund Holdings in GANX
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
| Added | 22.18% | $558,163 | <0.01% | ||||
| Greenlight Capital Inc | Not Changed | 0.00% | $1,194,472 | 0.06% | |||
| Gotham Asset Management LLC | Not Changed | 0.00% | $321,055 | <0.01% |
FAQ
Which hedge funds hold Gain Therapeutics?
The hedge funds that hold the most shares in Gain Therapeutics are BlackRock, Inc., Joel Greenblatt and David Einhorn.
Are hedge funds buying or selling GANX?
Currently, no data Available
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Gain Therapeutics stock?
Warren Buffet currently does not own shares in Gain Therapeutics.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here

